MEN11467 

MEN11467 is a selective and orally- effective peptidomimetic tachykinin NK₁ receptor antagonist.

Tachykinin NK₁ receptor^[1]

MEN11467 potently inhibits the binding of [³H] substance P (SP) to tachykinin NK₁ receptors in the IM9 limphoblastoid cell line (pK_i=9.4±0.1). MEN11467 is highly specific for the human tachykinin NK₁ receptors, since it has negligible effects (pK_i<6) on the binding of specific ligands to tachykinin NK₂ or NK₃ receptors and to a panel of 30 receptors ion channels unrelated to tachykinin receptors. The antagonism exerted by MEN11467 at tachykinin NK₁ receptors is insurmountable in saturation binding experiments, both K_D and B_max of SP are significantly reduced by MEN11467 (0.3-10 nM). In the guinea-pig isolated ileum, MEN11467 (0.03-1 nM) produces a nonparallel rightward shift of the concentration-response curve to SP methylester with a concomitant reduction of the E_max to the agonist (pK_B=10.7±0.1). Moreover the antagonist activity of MEN11467 is hardly reversible despite prolonged washout^[1]. The pseudopeptide tachykinin NK₁ receptor antagonist, MEN11467 is used to study tachykininergic involvement in antigen-induced mucus secretion in ferret trachea in vitro. MEN11467 (1 nM-10 μM) inhibits [Sar⁹]SP-induced ³⁵SO₄, output in a concentration-dependent manner with an approximate IC₅₀ of 0.3  μM^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

MEN11467 produces a long lasting (>2-3 h) dose-dependent antagonism of bronchoconstriction induced by the selective tachykinin NK₁ receptor agonist, [Sar⁹, Met(O₂)¹¹]SP in anaesthetized guinea-pigs (ID₅₀s=29±5, 31±12 and 670±270 μg/kg, after intravenous, intranasal and intraduodenal administration, respectively), without affecting bronchoconstriction induced by methacholine. After oral administration MEN11467 produces a dose-dependent inhibition of plasma protein extravasation induced in guinea-pig bronchi by [Sar⁹, Met(O₂)¹¹] (ID₅₀= 6.7±2 mg/kg) or by antigen challenge in sensitized animals (ID₅₀=1.3 mg/kg). After i.v. administration MEN11467 weakly inhibits the GR 73632-induced foot tapping behaviour in gerbil (ED₅₀=2.96±2 mg/kg), indicating a poor ability to block central tachykinin NK₁ receptors^[1]. Treatment with MEN11467 (1 mmol/kg twice weekly for 2 weeks) results in a temporary growth arrest of the U373 MG xenograft that last for about 10 days until the last MEN11467 administration (TVI%=56). Thereafter, the tumor start to regrow. MEN11467 anti-tumor activity is partially reverted by the simultaneous administration of an equimolar dose of exogenous substance P (SP), suggesting the specificity of tachykinin NK1 receptor activation in glioma growth. Prolonged s.c. treatment with a higher MEN11467 dose (1.7 mmol/kg at five times a week for 6 weeks) completely inhibits the growth of U373 MG tumor for the entire length of the experiment, even following administration of a low exogenous SP dose. After 6 weeks, the tumor mass is not increased compared to the untreated control with TVI%=96%^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

600.75

C₃₈H₄₀N₄O₃

214487-46-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Cirillo R, et al. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist. Neuropeptides. 2001 Jun-Aug;35(3-4):137-47.  [Content Brief]

  [2]. Khan S, et al. Effect of the long-acting tachykinin NK(1) receptor antagonist MEN 11467 on tracheal mucus secretion in allergic ferrets. Br J Pharmacol. 2001 Jan;132(1):189-96.  [Content Brief]

  [3]. Palma C, et al. Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer. 2000 Jan;82(2):480-7.  [Content Brief]